<SEC-DOCUMENT>0001193125-17-225433.txt : 20170711
<SEC-HEADER>0001193125-17-225433.hdr.sgml : 20170711
<ACCEPTANCE-DATETIME>20170710193402
ACCESSION NUMBER:		0001193125-17-225433
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170710
FILED AS OF DATE:		20170711
DATE AS OF CHANGE:		20170710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		17958850

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d423717d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July&nbsp;10, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED
LTD </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 10, 2017 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PRIMA BIOMED LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PRIMA BIOMED ANNOUNCES APPROVAL FOR THE INITIATION OF THE &#145;INSIGHT&#146; CLINICAL TRIAL</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d423717dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g423717g0710173851519.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10&nbsp;July 2017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED ANNOUNCES
APPROVAL FOR THE INITIATION OF THE &#145;INSIGHT&#146; CLINICAL TRIAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD)
(&#147;Prima&#148; the &#147;Company&#148;) today announced that its collaboration partner, the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany (&#147;IKF&#148;), has received the regulatory and ethical
approvals for the clinical trial investigating IMP321 in new settings, called &#148;INSIGHT&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval has been received from the
Paul-Ehrlich-Institut (&#147;PEI&#148;), the Federal Institute for Vaccines and Biomedicines for the German Federal Ministry of Health, which is the competent regulatory authority in the field of medicinal products that assesses and monitors
antibodies for the treatment of cancer and autoimmune diseases for human use. Approval has also been received from the Institute of Clinical Cancer Research ethics committee. The clinical trial will commence in due course. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investigator sponsored INSIGHT clinical trial will explore different routes of administration of IMP321 in solid tumours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead investigator of the study, Dr Salah-Eddin Al-Batran, commented, &#147;We are thrilled by the prospect of injecting an active immunotherapy directly
at the tumour site to see whether the locally induced antigen presenting cell activation leads to a regression of distant tumour masses, a characteristic of anti-tumour CD8 T cell responses. In addition, analysis of local tumour biopsies before and
after IMP321 injection will inform us about the immune infiltrates induced by this APC activator.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, Chief Executive of Prima, commented,
&#147;We are pleased to see the initiation of this new therapeutic application for IMP321. It is the first ever investigation of whether direct injection of IMP321 into a solid tumour can activate the antigen presenting cells located inside the
tumour to boost the body&#146;s immune response.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INSIGHT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INSIGHT is an explorative, single centre, open-label, Phase I clinical trial to evaluate the feasibility and safety of intra-tumoural, intra-peritoneal, and
subcutaneous injections with IMP321 <FONT STYLE="white-space:nowrap">(LAG-3Ig</FONT> fusion protein) for advanced stage solid tumour entities. The Lead Investigator of this up to 40 patient clinical trial is Professor Doctor Salah-Eddin Al-Batran,
the Medical Director of the IKF. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune
control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein, is an APC activator boosting T cell responses. IMP321 is currently
in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov
identifier <U>NCT 02676869</U>). A number of additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima&#146;s pharmaceutical
partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit
<U>www.primabiomed.com.au</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (2) 8234 0100;
<U>mgregorowski@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT
STYLE="white-space:nowrap">378-2933;</FONT> <U>mbeck@troutgroup.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level&nbsp;12, 95 Pitt Street, Sydney NSW
2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g423717g0710173851519.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g423717g0710173851519.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D RX# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %0W/^K'UJ:H;G_5CZT 34444 %%%% !1110 4444
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MLL3!T895AT(I /HHHH **** "H;G_5CZU-4-S_JQ]: )J*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"6YJOK,>Q#RZIW1WF:,UQ"Z]?+UDS^%2KXDO!UVFG]8B0\OK'9T5R(\3W
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M_.CS$_OK^= 6'44SS8_[Z_G1YL?_ #T7\Z!V8^BH_/B_YZ)^='GP_P#/5/\
MOJBX69)147VF#_GLG_?0IC7UJO6XC'_ A1=!ROL6**I-JMBGWKN$?\"%0OK^
MEQ_>OH?^^J7,NY2IS>R-.BL5O%6BIUOHOP-0/XUT)!S>J?H*GVD.YHL-6>T'
M]QT-%<P?'FA#_EY)_"H6^(6B+_RT<_1:/:P[E+!XA_8?W'6T5QLGQ(T=1\HE
M;\*IR?$^Q7[EK(U3[>GW-%EV*?V&=]17G#?%)/X;%OQ-0/\ %&7^"S4?4U/U
MFGW-%E6+?V3T[-)FO)I?B;J3?ZNWC6L^;Q_KDI.)53Z"I>*IFT<EQ+WM]Y[3
MD4%@.I%>$2>,-=D/-\X^E59/$6K2_?OYCG_:J'C(]$;+(:W62/?)+NWB&7FC
M7ZL*I2^(-)A^_?PC_@5>"2WMU,<R7$K?5C4!)/4DU/UQ]$=$<@7VI_@>[3>,
M]"A'-ZA^E9-W\2=(AXB$DOT%>/TE0\7/H;PR.@OB;9Z;+\4XQGRK)C]355?B
M7<W$A4VB!0,CFO.ZL6?^M/\ NU"Q%1O<WEE6%C!^Z?1]%%%>H?&!1110 444
M4 %%%% !1110 4444 %%%% !1@>E%% $3P1/]Z)#]5JN^EV+_?M8C_P&KM%*
MR*4I+9F+/X7TFX^]:H/]WBL^7P'I3_=WK]#758HJ73@]T:QQ5:.TF<5)\/;0
MCY+AQ]:HS?#R<?ZFY4_[PKT.BH>'IOH;QS+$Q^T>72>!M5C/RB-_H:K2>$=9
MC'_'J3]#7K.*,5F\)!FRS>NM['C<FB:E%P]I*/PJ$V5RGWH)!]5KVHJ#U%,,
M$3?>C4_45#P<>C-5G$^L3Q0HZ]58?445[))IEE*,/;1G_@-4I/#.E2')M5'T
MJ'@Y=&;+.(/>)Y53ATKTJ3P?I;=(V7Z&JDO@>S8?NYG6I>%J(U6:4'O='!4H
MKKW\"29_=W0_$5 _@F^7[DL;?C4O#U%T-%C\._M'-4X5M2>$]4C_ .68;Z&J
MCZ+J,7WK5_P%3[.:W1JL12>TD4LTX&IC872?>MY!^%,,,J_>C8?A4V97-%[,
M2G"FX/H:=2 >*=GBF4X&F)D@Z4X5&*<#5$LDIP-1YI:";#\T9IN:,T[A87-(
M:2D)I!84]*92YIA-)C"F&ES332*0AIAIQ--H*0E,-.---(I#:0]:6FDTF.PA
MINX]B?SI>M-/6@:2#S''\;?G1YTHZ2/_ -]&F&DHN59#S<3C_EL__?1I/M=P
M/^6\G_?1J,TTTN9ARKL2F\N>T\G_ 'T:/MUU_P _$O\ WT:@I#1S,?)'L3_V
MA>?\_,O_ 'U2?VC>_P#/U+_WU5>D/6CF8_9P[%C^TKW_ )^Y?^^J3^U+[_G[
MF_[ZJM3*?.Q^SAV+1U2__P"?N;_OJD_M6_\ ^?N;_OJJIIM',^Y7LH=BW_:M
M_P#\_DW_ 'U3?[4O_P#G\F_[[-532'I1S/N/V4.Q:.J7_P#S^3?]]TW^T[__
M )^YO^^S54TAZ4N9C5.'9%DZG>_\_<W_ 'T:C.HWA_Y>I?\ OLU :;1S/N-4
MX=BP;Z[/_+S+_P!]FFF\NN]Q+_WV:AI#1=E*$5T)#=7!_P"6\G_?1IAGE/65
M_P#OHTPTVBY7*NPXN[=78_C33GN3124KE)(*2EI*!B&DI324 ':DI:2F,***
M*!@>E-IQZ4VD,2BBB@04444P"D/6@TE(858L_P#6G_=JO5BS_P!:?]VG'<BI
M\#/H^BBBO;/SL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $HQ2T4 )BC%+10 F*,4M% ##&IZJ#^%,:U@<?-
M$A_"IJ*+(:;6Q2;2K)^MO'^50OH&G/UMU'TK3HJ7&+W1:JS6S9A2>%-/?H&7
MZ&JS>#K?^"=Q]17345+I0?0TCBZT=I'*-X.Q]VY_-:K2>$[E?N2HU=I28J?8
M4^QHL=774X1_#FH+_P LP?H:A;1=07K U>@XHQ4O#1-%F57JD><MIUZGWK=_
MRJ!HID^]&P_"O3, ]J88(F^]&I_"I^JKHS19G+K$\RY[@TA.*]*:PM6^];H?
M^ U"VD6#=;9/RJ7A7W-%F<>L3SDFFD\UZ!)X=TZ3_ECCZ&H&\*:>>@<?C4O#
M3Z&BS*EU3.%S32:[9_"%J?NRN*K2>#!C]W<_F*AX>HNAK',*#ZG(=:::Z9_!
MUX/N2H:KMX1U)>@0_0U#HU.QLL90?VCGCZ4VMM_"^IK_ ,L<_0U5DT/4HOO6
MKX]A4.$^QK&O2>TD9IIIJR]E=)]Z"0?\!J$P3#K&X_X#4M,U4XO9D6:;3V1A
MU4C\*8<TBT----.[TTTBAM(:6DI#&FF]J<:;0,::0GBE---!0'I3*<>E-H&(
M:;3C3304(:::6DH&(:0]*6D/2@8TTVE-)0,#TIM*:2@8AI!TI32#I04)24II
M* "DI:0T#$-)110 4E+24QA1110,#TIM./2FTAB4444""BBBF AI*4TE(858
ML_\ 6G_=JO5BS_UI_P!VG'<BI\#/H^BBBO;/SL**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I",
MTM% #/+0]5!_"FFWA;K$A_X#4M%&@[LJM86C_>MXC_P&JTF@Z9+]ZTC_  %:
M=%)QB^A2J36S9A2>$M(D_P"6!'T:J[>"M+8<"0?\"KI:*ETH/H:+%5H[29R;
M^!+!ONS2"JLGP_A/^KNV'U%=MBBI]A3[&JQ^(7VC@'^'\H^[=J?PJ%O %Y_#
M<1FO1:*AX:GV-%F>)74\PE\"ZFOW3&WT-5)/!^L(>+?=]#7K5%)X2F:1S;$+
M>QXU)X:U=>ME)^ JN^B:FGWK*8?\!KVW%)@>E3]3CW-5G-1;Q1X:VF7J_>M9
MA_P U7>WF3[T3CZK7O112.5!_"HVM;=_O01GZJ*AX-=S19V^L/Q/!"".H---
M>Z2:/ITGW[*$_P# !59_#6COUL(OP%3]3EW-HYW3ZQ9XG3:]G;PCHK'_ (\E
M'T-1/X(T1QQ;$?1J7U.?<T6=4.J9XV>M)7K4GP]TA\[?,7Z&J<GPVLF^Y=2+
M]14O"5#6.<89[W1YC3#UKTA_ADO\%\?Q6H&^&,W\-ZOXK4_5JG8U6:85_:_,
M\]/2DKO&^&5[_#=Q'\*KO\-]57[LL3?C2]A4[&BS+"O[:.+I*ZM_A]KB](XV
M^C5 W@77E_Y=0?HU3[&IV-%C<,]IHYJ@]*WV\&:ZO_+BY^E5W\*ZVG73YORI
M>SEV-%B:+VFOO,:BM"30M5B^_83C_@!JN]C=I]^VF'U0U/*^QHJD'LT5J*>T
M,HZQN/PINQO[I_*@OF3V$HI=K>A_*DYH'<0FDHHI%"4444""BDS2TP$-)2FD
MI#"K%G_K3_NU7JQ9_P"M/^[3CN14^!GT?1117MGYV%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F*6B@ HQ110
M 4F*6BF F*7%%%( HHHH 3%&*6B@!,48I:*8"8IC01O]Z-3]14E%("LUA:-U
MMH3_ , %1G2=/;K9P'_@ J[11RIE*<ELS-;0-*?[UC ?^ U"_A?17ZZ?#^ K
M8HI<D>Q2K5%M)_><_)X*T&3K8H/H:J2?#W09.D+K]&KJZ*GV4.QJL9B%M-_>
M<6_PST9ONM,O_ J@;X7:6>EQ,*[NBE["GV+688I?;9Y\WPML3]V\E'U%0O\
M"N'^#4'_ !6O1L4M+ZO3[%K-,6OMGF$GPJD_@U ?BM59/A9J _U=Y"WU!KUF
MBI^JTNQJLXQ:^U^!XX_PSUM?N- W_ J;%\/M=@<L\<6",</7LM0W/^K'UI?5
M:93SG%-6=ON):***Z3R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN?]6/K110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
